ENDRA Life Sciences (NDRA) shares more than doubled Tuesday after the company said a post market clinical study was started at the LMU University Hospital in Munich, Germany to assess the liver fat measurement capabilities of its TAEUS system.
The company said a first patient was scanned with the TAEUS system in the study, which is designed to assess the system's utility for managing metabolic disease.
ENDRA said it expects the collaboration with LMU researchers to augment clinical data and support the company's de novo submission to the US Food and Drug Administration by mid-2025.
Price: 0.49, Change: +0.27, Percent Change: +124.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。